Präzisionsmedizin – die Antwort der Medizin auf Diversität?
-
Elisabeth-Herz-Kremenak-Saal
Plenary
/
in englischer SpracheParadigmenwechsel in der Medizin: Präzisionsmedizin! Diversität, als Grundlage dieser revolutionären Entwicklung, verändert die Medizin nachhaltig hin zu personalisierten Behandlungsmethoden. Welche Vorteile ergeben sich für die einzelnen PatientInnen? Erleben wir eine medizinische Revolution? Und was bedeutet das für die Technologien von morgen?
| |||||
| |||||
| |||||
| |||||
|
Dr. MD Christian J. HEROLD
Leiter, Abteilung für Allgemeine Radiologie und Kinderradiologie, Medizinische Universität Wien
| 1973-1979 | Medical Training - University of Vienna |
| 1979 | Graduation M.D. |
| 1979-1984 | Internship and Training as General Practitioner |
| 1984 | Board Certification as GP |
| 1984-1989 | Residency in Radiology - University of Vienna |
| 09.1989 Board Certification | |
| 1989-1991 | Postdoctoral Training |
| Research Fellowship in Chest Radiology and MR Imaging, Dept. of Radiology Johns Hopkins University, Baltimore, USA | |
| since 1992 | Faculty member (part time), Dept. of Radiology, Johns Hopkins Hospital, Baltimore USA |
| Chief Executive Officer of MUVI (Medical University of Vienna International Hospital Operations) | |
| Designated Chairman; Department of Radiology and Radiologic Clinics, Medical University of Vienna (from 10/2008) | |
| Director, International Affairs, Medical University of Vienna | |
| Vienna Health Council, Board Member |
Ph.D. Peter NILSSON
Professor in Proteomics and Scientific Director, SciLifeLab, Department of Protein Science, KTH - Royal Institute of Technology, Stockholm
| 1993 | M.Sc., Biotechnology, KTH Royal Institute of Technology, Stockholm |
| 1999 | Ph.D., Biotechnology, KTH Royal Institute of Technology, Stockholm |
| since 2002 | Head, Affinity Proteomics research group, KTH Royal Institute of Technology, Stockholm |
| 2007 | Associate professor, Biotechnology, KTH Royal Institute of Technology, Stockholm |
| 2011 | Professor in Proteomics, KTH Royal Institute of Technology, Stockholm |
| 2011-2016 | Site Director, Human Protein Atlas, SciLifeLab Stockholm |
| 2014-2017 | Director, SciLifeLab Affinity Proteomics national platform, Solna |
| Vice Dean, School of Biotechnology, KTH Royal Institute of Technology, Stockholm | |
| since 2014 | Director, SciLifeLab Autoimmunity profiling facility, Solna |
| since 2017 | Scientific Director, SciLifeLab, KTH Royal Institute of Technology, Stockholm |
Ph.D. Patrice MILOS
President and CEO, Medley Genomics, Providence, RI
| 1980-1984 | Ph.D., Biology, Rensselaer Polytechnic Institute, NY |
| 1984-1987 | Post-Doctoral Fellow, The Biological Laboratories, Harvard University, MA |
| 1987-1990 | Post-Doctoral Fellow, Brown University, RI |
| 1993-2007 | Executive Director, Global Research & Development, Pfizer Inc., CT |
| Executive Director, Translational and Molecular Medicine, Pfizer Inc., CT. | |
| 2007-2011 | Senior Vice President; CSO, Helicos BioSciences, MA |
| 2011-2013 | Site Head, Centers for Therapeutic Innovation, Pfizer Inc., MA |
| 2013-2016 | President, CEO, Claritas Genomics, MA |
| since 2015 | Scientific Advisor SeqLL - ULTRAPLACAD - Baby's First Test |
| since 2016 | Co-Founder, President and CEO, Medley Genomics, RI |
| since 2017 | Board of Directors, MedMates, RI BIO Affiliate, RI |
| since 2018 | Scientific Advisor, Atlas Genetics, Trowbridge |
DI Dr. Michaela FRITZ
Vice Rector for Research and Innovation, Medical University of Vienna; Member of the Steering Committee, European Forum Alpbach, Vienna
| 1989-1994 | Master studies, Department of Materials Science, ETH Zurich |
| 1994-1995 | Diploma thesis, Washington Research Centre, W. R. Grace, Columbia, Maryland, MD |
| 1995-1998 | Research assistant; Teaching assistant, Laboratory for Surface Science and Technology, ETH Zurich |
| 1996-2000 | Ph.D. studies, Department of Materials Science, ETH Zurich |
| 2000-2001 | Ph.D. scientist, Department of Chemical Engineering, University of California, Berkeley, CA |
| 2001-2004 | Business development, Bioscience, Infineon Technologies AG, Munich |
| 2005-2010 | Head, LISA - Life Sciences Austria, Technology & Innovation, Austria Wirtschaftsservice GmbH, Vienna |
| 2006-2010 | Managing Director, LISA VR, Life Science Austria Vienna Region, Vienna |
| 2010-2015 | Head, Department Health and Environment, AIT - Austrian Institute of Technology, Vienna |
| 2012-2016 | President, AAL Austria, Vienna |
| since 2015 | Vice-Rector, Research and Innovation, Medical University Vienna |
| Member, Scientific Advisory Committee, Joanneum Research, Vienna | |
| since 2018 | Head, Scientific Advisory Committee Health Symposium and Member of the Steering Committee, European Forum Alpbach, Vienna |
Dr. Giulio SUPERTI-FURGA
Professor, Institute of Pharmacology, Medical University of Vienna; Scientific Director, CeMM - Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna
| 1987-1991 | Ph.D., Molecular Biology, University of Zurich |
| 1991-1993 | Postdoctoral fellow, EMBO and EU Postdoc EMBL - European Molecular Biology Laboratory, Heidelberg |
| 1993-2004 | Staff Scientist, Team Leader; EMBL - European Molecular Biology Laboratory, Heidelberg |
| 1997-2000 | Guest Professor, Molecular Biology, University of Bologna |
| 2000-2005 | Founder and Scientific Director, Cellzome AG and Inc., Heidelberg and Cambridge |
| 2005-2014 | Guest Professor, Molecular Pharmacology, Medical University of Vienna |
| since 2005 | Director, CeMM - Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna |
| since 2015 | Professor, Medical Systems Biology, Center for Physiology and Pharmacology, Medical University of Vienna |
| since 2017 | Member, Scientific Council of the European Research Council, Brussels |
